We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma (BRd)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01701076
Recruitment Status : Completed
First Posted : October 4, 2012
Last Update Posted : August 24, 2016
Celgene Corporation
Mundipharma Research GmbH & Co KG
Mundipharma Medical Company
Information provided by (Responsible Party):
PD Dr. Ulrich Mey, Kantonsspital Graubünden

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : February 2016
  Study Completion Date : February 2016